Yuyu Pharma, Inc. (000227.KS)
KRW 9750.0
(-0.41%)
KRW 9750.0
(-0.41%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 137.2 Billion KRW | -1.2% |
| 2022 | 138.88 Billion KRW | 20.08% |
| 2021 | 115.65 Billion KRW | 17.87% |
| 2020 | 98.11 Billion KRW | 7.97% |
| 2019 | 90.87 Billion KRW | 9.36% |
| 2018 | 83.09 Billion KRW | 32.21% |
| 2017 | 62.85 Billion KRW | -12.19% |
| 2016 | 71.57 Billion KRW | 2.63% |
| 2015 | 69.74 Billion KRW | 11.03% |
| 2014 | 62.81 Billion KRW | 1.33% |
| 2013 | 61.99 Billion KRW | 0.02% |
| 2012 | 61.98 Billion KRW | 5.42% |
| 2011 | 58.79 Billion KRW | 13.02% |
| 2010 | 52.02 Billion KRW | 8.62% |
| 2009 | 47.9 Billion KRW | 6.41% |
| 2008 | 45.01 Billion KRW | -39.04% |
| 2007 | 73.84 Billion KRW | 0.61% |
| 2006 | 73.39 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 33.17 Billion KRW | -0.68% |
| 2024 Q1 | 33.4 Billion KRW | -3.48% |
| 2023 Q1 | 34.29 Billion KRW | -1.28% |
| 2023 Q2 | 34.21 Billion KRW | -0.23% |
| 2023 Q4 | 34.6 Billion KRW | 1.52% |
| 2023 FY | 137.2 Billion KRW | -1.2% |
| 2023 Q3 | 34.09 Billion KRW | -0.37% |
| 2022 Q2 | 34.47 Billion KRW | -2.96% |
| 2022 FY | 138.88 Billion KRW | 20.08% |
| 2022 Q4 | 34.73 Billion KRW | 1.75% |
| 2022 Q1 | 35.52 Billion KRW | 14.06% |
| 2022 Q3 | 34.14 Billion KRW | -0.96% |
| 2021 FY | 115.65 Billion KRW | 17.87% |
| 2021 Q1 | 26.49 Billion KRW | 7.42% |
| 2021 Q2 | 28.22 Billion KRW | 6.55% |
| 2021 Q3 | 29.78 Billion KRW | 5.5% |
| 2021 Q4 | 31.14 Billion KRW | 4.58% |
| 2020 Q1 | 23.23 Billion KRW | -5.1% |
| 2020 Q3 | 25.5 Billion KRW | 3.16% |
| 2020 Q4 | 24.66 Billion KRW | -3.27% |
| 2020 FY | 98.11 Billion KRW | 7.97% |
| 2020 Q2 | 24.71 Billion KRW | 6.39% |
| 2019 Q1 | 22.15 Billion KRW | 0.38% |
| 2019 Q2 | 22.7 Billion KRW | 2.47% |
| 2019 FY | 90.87 Billion KRW | 9.36% |
| 2019 Q4 | 24.48 Billion KRW | 13.66% |
| 2019 Q3 | 21.54 Billion KRW | -5.11% |
| 2018 Q1 | 21.49 Billion KRW | 0.0% |
| 2018 FY | 83.09 Billion KRW | 32.21% |
| 2018 Q2 | 20.15 Billion KRW | -6.2% |
| 2018 Q4 | 22.07 Billion KRW | 13.9% |
| 2018 Q3 | 19.37 Billion KRW | -3.87% |
| 2017 Q3 | 21.07 Billion KRW | 3.95% |
| 2017 Q1 | 20.92 Billion KRW | 9.39% |
| 2017 FY | 62.85 Billion KRW | -12.19% |
| 2017 Q2 | 20.27 Billion KRW | -3.14% |
| 2016 Q4 | 19.13 Billion KRW | 16.63% |
| 2016 Q1 | 20.59 Billion KRW | 19.5% |
| 2016 FY | 71.57 Billion KRW | 2.63% |
| 2016 Q3 | 16.4 Billion KRW | 8.54% |
| 2016 Q2 | 15.11 Billion KRW | -26.63% |
| 2015 FY | 69.74 Billion KRW | 11.03% |
| 2015 Q4 | 17.23 Billion KRW | 0.61% |
| 2015 Q3 | 17.13 Billion KRW | 15.94% |
| 2015 Q2 | 14.77 Billion KRW | -13.65% |
| 2015 Q1 | 17.11 Billion KRW | 3.11% |
| 2014 Q3 | 16.25 Billion KRW | 26.43% |
| 2014 FY | 62.81 Billion KRW | 1.33% |
| 2014 Q4 | 16.59 Billion KRW | 2.14% |
| 2014 Q1 | 16.21 Billion KRW | 4.15% |
| 2014 Q2 | 12.85 Billion KRW | -20.74% |
| 2013 Q4 | 15.57 Billion KRW | 2.76% |
| 2013 Q1 | 16.87 Billion KRW | 15.22% |
| 2013 Q2 | 15.05 Billion KRW | -10.79% |
| 2013 Q3 | 15.15 Billion KRW | 0.66% |
| 2013 FY | 61.99 Billion KRW | 0.02% |
| 2012 Q3 | 14.99 Billion KRW | -3.08% |
| 2012 Q4 | 14.64 Billion KRW | -2.32% |
| 2012 FY | 61.98 Billion KRW | 5.42% |
| 2012 Q2 | 15.47 Billion KRW | 0.0% |
| 2012 Q1 | - KRW | -100.0% |
| 2011 Q3 | 13.54 Billion KRW | 4.1% |
| 2011 Q2 | 13 Billion KRW | -12.57% |
| 2011 FY | 58.79 Billion KRW | 13.02% |
| 2011 Q1 | 14.87 Billion KRW | 2.8% |
| 2011 Q4 | 14.46 Billion KRW | 6.85% |
| 2010 Q4 | 14.47 Billion KRW | 30.44% |
| 2010 Q3 | 11.09 Billion KRW | -4.24% |
| 2010 Q2 | 11.58 Billion KRW | -24.64% |
| 2010 Q1 | 15.37 Billion KRW | 14.37% |
| 2010 FY | 52.02 Billion KRW | 8.62% |
| 2009 Q4 | 13.44 Billion KRW | 19.46% |
| 2009 Q3 | 11.25 Billion KRW | 43.67% |
| 2009 Q1 | 7.37 Billion KRW | -14.62% |
| 2009 Q2 | 7.83 Billion KRW | 6.18% |
| 2009 FY | 47.9 Billion KRW | 6.41% |
| 2008 Q1 | 16.95 Billion KRW | -21.28% |
| 2008 FY | 45.01 Billion KRW | -39.04% |
| 2008 Q4 | 8.63 Billion KRW | -39.25% |
| 2008 Q3 | 14.22 Billion KRW | -3.77% |
| 2008 Q2 | 14.77 Billion KRW | -12.81% |
| 2007 FY | 73.84 Billion KRW | 0.61% |
| 2007 Q2 | 16.73 Billion KRW | 0.0% |
| 2007 Q3 | 18.61 Billion KRW | 11.22% |
| 2007 Q4 | 21.53 Billion KRW | 15.65% |
| 2006 FY | 73.39 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 87.879% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 78.509% |
| HANDOK Inc. | 522.74 Billion KRW | 73.752% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -1.357% |
| Yuhan Corporation | 1858.98 Billion KRW | 92.619% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 79.335% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -164.093% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 90.797% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -1.705% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 62.97% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -54.875% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | 19.083% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 38.87% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 0.0% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -75.79% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | 9.176% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -57.056% |
| JW Holdings Corporation | 928.07 Billion KRW | 85.216% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 77.161% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 91.781% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 81.669% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 31.474% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | 24.094% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 30.118% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 81.111% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 0.0% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 90.94% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 90.024% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 81.669% |
| Yuhan Corporation | 1858.98 Billion KRW | 92.619% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 82.735% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 41.589% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 76.923% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 81.669% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 53.031% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 50.811% |
| CKD Bio Corp. | 160.35 Billion KRW | 14.433% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 73.962% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 62.003% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 40.446% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 31.474% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 84.404% |
| Boryung Corporation | 859.62 Billion KRW | 84.038% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -8.959% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 62.97% |
| JW Lifescience Corporation | 206.86 Billion KRW | 33.67% |